Setting the Standard in CML Testing: Anchor Molecular’s BCR-ABL1 RNA Controls

In the landscape of chronic myeloid leukemia (CML) diagnostics, precision is everything. The ability to detect and quantify BCR-ABL1 fusion transcripts with accuracy is essential for diagnosis, treatment monitoring, and long-term disease management. At Anchor Molecular, we are proud to offer high-quality, WHO-traceable BCR-ABL1 RNA standards that empower laboratories to deliver confident, consistent results.

The Importance of BCR-ABL1 in CML

CML is characterized by the presence of the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that creates the BCR-ABL1 fusion gene. This gene encodes a constitutively active tyrosine kinase that drives leukemic cell proliferation.

Monitoring BCR-ABL1 transcript levels is critical for:-

• Confirming diagnosis
• Assessing treatment response
• Tracking minimal residual disease (MRD)
• Guiding therapeutic decisions over time

Why High-Quality RNA Standards Matter

Quantitative molecular assays—such as RT-qPCR—are the gold standard for monitoring BCR-ABL1 levels. However, these assays require reliable, standardized reference materials to ensure accuracy and reproducibility. Poor-quality or inconsistent standards can lead to misinterpretation of patient results, potentially affecting clinical outcomes.

Anchor Molecular’s BCR-ABL1 RNA Standards

Anchor Molecular offers purified RNA standards traceable to the WHO International Standard, ensuring global harmonization and confidence in your results. Our standard set includes the three most clinically relevant BCR-ABL1 fusion transcripts:-

• p210 e14a2
• p210 e13a2
• p190 e1a2

These variants are essential for comprehensive CML testing and are fully compatible with Cepheid’s GeneXpert® p190 and p210 assays, making them ideal for both clinical diagnostics and assay development.

What Makes Anchor Molecular’s Standards Exceptional?

✅ WHO-traceable: Ensures international consistency and regulatory compliance.

✅ High-purity RNA: Delivers consistent, reproducible performance.

✅ Broad coverage: Includes the most common CML-associated fusion variants.

✅ Platform compatibility: Validated for use with leading diagnostic systems.

Supporting Precision Hematology

At Anchor Molecular, we understand that accurate quantification of BCR-ABL1 is critical to managing CML effectively. Our RNA standards are designed to support laboratories in delivering high-confidence results that directly impact patient care.